Janet Hammond
Fortune : 596 196 $ au 31/05/2026
Fortune : 596 196 $ au 31/05/2026
Janet Hammond currently works at Enterprise Therapeutics Ltd., as Director from 2024, Atea Pharmaceuticals, Inc., as Chief Development Officer from 2020, and Roche Ltd., as Vice President-Translational Medicine from 2011.
Dr. Hammond also formerly worked at Bristol Myers Squibb Co., as Group Director-Virology Clinical Research, Bausch Health Americas, Inc., as Chief Medical Officer, SVP & Head-Medical Affairs, F.
Hoffmann-La Roche Ltd., as SVP & Head-China Infectious Disease from 2011 to 2016, Valeant Pharmaceutical, as Chief Medical Officer, SVP & Head-Medical Affairs, AbbVie, Inc., as VP, Head-General Medicine & Infectious Disease from 2016 to 2020, GSK Plc, as Head-Clinical Discovery, and Glaxo Wellcome, Inc., as Senior Clinical Research Physician.
Dr. Hammond received her doctorate degree from the University of Cape Town and graduate degree from Johns Hopkins Bloomberg School of Public Health.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
| 24/04/2026 | 127 665 ( 0,16 % ) | 596 196 $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| ATEA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/08/2020 |
Roche Ltd.
Roche Ltd. Financial ConglomeratesFinance Provides investment services | Corporate Officer/Principal | 29/03/2011 |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Develops novel therapies to patients suffering with respiratory diseases | Directeur/Membre du Conseil | 01/05/2024 |
| Sociétés | Poste | Fin |
|---|---|---|
| ABBVIE INC. | Corporate Officer/Principal | 01/08/2020 |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Corporate Officer/Principal | 01/11/2016 |
Bausch Health Americas, Inc.
Bausch Health Americas, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceuticals | Directeur Technique/Scientifique/R&D | 12/09/2011 |
Valeant Pharmaceutical | Directeur Technique/Scientifique/R&D | - |
| BRISTOL-MYERS SQUIBB COMPANY | Directeur Technique/Scientifique/R&D | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 12 |
|---|---|
Bristol Myers Squibb Co.
Bristol Myers Squibb Co. Pharmaceuticals: MajorHealth Technology Manufactures and markets biopharmaceuticals products | Health Technology |
Bausch Health Americas, Inc.
Bausch Health Americas, Inc. Pharmaceuticals: MajorHealth Technology Manufactures and distributes pharmaceuticals | Health Technology |
F. Hoffmann-La Roche Ltd.
F. Hoffmann-La Roche Ltd. Pharmaceuticals: MajorHealth Technology Manufactures pharmaceutical products | Health Technology |
AbbVie, Inc.
AbbVie, Inc. Pharmaceuticals: MajorHealth Technology Engages in the research and development, manufacturing, commercialization & sale of immunology medicines and therapies | Health Technology |
Atea Pharmaceuticals, Inc.
Atea Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Discovers, develops and commercializes antiviral therapeutics | Health Technology |
GSK Plc
GSK Plc Pharmaceuticals: MajorHealth Technology Develops, manufactures and distributes vaccines and other pharmaceutical products | Health Technology |
University of Cape Town
University of Cape Town Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Roche Ltd.
Roche Ltd. Financial ConglomeratesFinance Provides investment services | Finance |
Glaxo Wellcome, Inc.
Glaxo Wellcome, Inc. Pharmaceuticals: MajorHealth Technology Engages in pharmaceutical preparations | Health Technology |
Johns Hopkins Bloomberg School of Public Health
Johns Hopkins Bloomberg School of Public Health Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Enterprise Therapeutics Ltd.
Enterprise Therapeutics Ltd. BiotechnologyHealth Technology Develops novel therapies to patients suffering with respiratory diseases | Health Technology |
Valeant Pharmaceutical |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national